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Identifying the Clinical Domains of Fibromyalgia:
Contributions From Clinician and Patient Delphi
Exercises
PHILLIP J. MEASE,1 LESLEY M. ARNOLD,2 LESLIE J. CROFFORD,3 DAVID A. WILLIAMS,4
I. JON RUSSELL,5 LOUISE HUMPHREY,6 LINDA ABETZ,6 AND SUSAN A. MARTIN7
Objective. In evaluating the effectiveness of fibromyalgia (FM) therapies, it is important to assess the impact of those
therapies on the full array of domains considered important by both clinicians and patients. The objective of this research
was to identify and prioritize the key clinically relevant and important domains impacted by FM that should be evaluated
by outcome assessment instruments used in FM clinical trials, and to approach consensus among clinicians and patients
on the priority of those domains to be assessed in clinical care and research.
Methods. Group consensus was achieved using the Delphi method, a structured process of consensus building via
questionnaires together with systematic and controlled opinion feedback. The Delphi exercises involved 23 clinicians
with expertise in FM and 100 patients with FM as defined by American College of Rheumatology criteria.
Results. The Delphi exercise revealed that the domains ranked most highly by patients were similar to the domain
rankings by clinicians. Pain was consistently ranked highest by both panels. Fatigue, impact on sleep, health-related
quality of life, comorbid depression, and cognitive difficulty were also ranked highly. Stiffness was ranked highly by
patients but not clinicians. In contrast, side effects was important to clinicians but was not identified as important in the
patient Delphi exercise.
Conclusion. The clinician and patient Delphi exercises identified and ranked key domains that need to be assessed in FM
research. Based on these results, a conceptual framework for measuring patient-reported outcomes is proposed.
INTRODUCTION
Fibromyalgia (FM) is a chronic disorder characterized by
persistent, widespread pain and tenderness (1). FM is es-
timated to occur in 2% of the US general population,
affecting more women than men (2). Symptoms frequently
associated with FM include fatigue, sleep disruption,
headache, memory or concentration problems, mood dis-
turbances, and irritable bowel symptoms (1,2). FM has a
substantial impact on daily life, limiting patients’ func-
tioning and negatively affecting emotional well-being
(3,4).
Recently, a number of large controlled trials have eval-
uated newly developed FM therapies that have effectively
distinguished placebo and treatment response in domains
Supported by Pfizer and the NIH (National Institute of
Arthritis and Musculoskeletal and Skin Diseases grant R01-
AR-05-3207).
1Phillip J. Mease, MD: Seattle Rheumatology Associates,
Seattle, Washington; 2Lesley M. Arnold, MD: University of
Cincinnati, Cincinnati, Ohio; 3Leslie J. Crofford, MD: Uni-
versity of Kentucky, Lexington; 4David A. Williams, PhD:
University of Michigan, Ann Arbor; 5I. Jon Russell, MD,
PhD: University of Texas, San Antonio; 6Louise Humphrey,
MSc, Linda Abetz, MA: Mapi Values, Bollington, UK; 7Su-
san A. Martin, MSPH: Pfizer, Ann Arbor, Michigan.
Dr. Mease has received consultant fees and grant/research
support (less than $10,000 each) from Pfizer, Cypress Bio-
sciences, Forest, Eli Lilly, Allergan, Fralex, Boehringer-
Ingelheim, Jazz, Wyeth, and Pierre Fabre, and has received
speaking fees (less than $10,000) from Pfizer. Dr. Arnold
has received consultant fees, speaking fees, and/or grant/
research support (less than $10,000 each) from Cypress Bio-
sciences, Boehringer-Ingelheim, Forest, Allergan, Organon,
Sanofi-Aventis, Sepracor, and Vivus, and (more than
$10,000 each) from Eli Lilly, Pfizer, and Wyeth. Dr. Crofford
has received consultant fees and/or grant/research support
(less than $10,000 each) from Pfizer, Eli Lilly, Allergan, and
Wyeth. Dr. Williams has received consultant fees (less than
$10,000 each) from Eli Lilly, Cypress Biosciences, Forest,
and Pierre Fabre. Dr. Russell has received consultant fees,
speaking fees, and/or honoraria (less than $10,000) from
Lilly and (more than $10,000 each) from Pfizer and Jazz. Ms
Humphrey and Ms Abetz received research/grant support
from Pfizer and were contracted by Pfizer to assist in the
present study. Ms Martin owns stock in Pfizer.
Address correspondence to Phillip J. Mease, MD, Seattle
Rheumatology Associates, 1101 Madison Street, Suite 1000,
Seattle, WA 98104. E-mail: pmease@nwlink.com.
Submitted for publication November 1, 2007; accepted in
revised form February 4, 2008.
Arthritis & Rheumatism (Arthritis Care & Research)
Vol. 59, No. 7, July 15, 2008, pp 952–960
DOI 10.1002/art.23826
© 2008, American College of Rheumatology
ORIGINAL ARTICLE
952
such as pain, fatigue, sleep, and function (5,6). However,
consensus has not yet been reached regarding the core
domains that should be assessed in all clinical trials of FM.
Achievement of consensus regarding core domains is im-
portant in the process of developing reliable and meaning-
ful outcome measures.
Consensus building takes time, and in order to facilitate
such a goal with regard to the core domains for FM, the
Delphi technique was used in the present study. The Del-
phi method, developed by the RAND Corporation (7), is a
structured process of consensus finding by means of a
distribution of questionnaires combined with systematic
and controlled opinion feedback (8–11). Historically, ap-
plications of the Delphi technique have sought opinions
from experts in their fields (12–14), with the use of non-
experts being less common (15). However, studies using
nonexperts have been conducted, showing good agree-
ment and demonstrating that the Delphi technique may be
applied among individuals who may not traditionally be
considered sufficiently knowledgeable for participation as
a Delphi panel member (15).
The Delphi method provides a unique insight for the
treatment of patients with FM because it can elicit and
account for both expert and nonexpert perspectives. It
could be argued that the most knowledgeable “expert”
impacted by a disease or condition is the patient living
with the disease and experiencing its effect daily. Clinical
experts, who see patients at a given point in time, must
rely on patients’ reports of their experiences over time to
make the most accurate clinical judgments. Together, the
clinician and patient could be the “expert” when deciding
which domains are clinically relevant and important to the
patient.
The results of the expert clinician Delphi exercise that
identified key clinical domains of FM were recently pub-
lished (16). However, it cannot be assumed that the same
domains will be considered equally important and rele-
vant by patients in comparison with clinicians. The Food
and Drug Administration’s guidance to industry on the use
of patient-reported outcome (PRO) measures highlights the
importance of including the patient perspective (17). It
states that many treatment effects are only known to the
patient and that formal PRO instruments are more reliable
than the clinician’s assessment of an informal interview.
The objective of the present study was to identify and
prioritize the key domains impacted by FM from a pa-
tient’s perspective using the Delphi method. These results
were compared with the previously completed expert cli-
nician Delphi (16). The goal was to approach consensus on
the priority of domains to be assessed in clinical care and
research among clinicians and patients.
PARTICIPANTS AND METHODS
Clinician Delphi methods. Full details of the clinician
Delphi panel have been previously presented by Mease et
al (16). Briefly, a list of 40 potential domains was prepared
through a literature review and discussion among the au-
thors (PJM, LMA, and LJC). Potential participants for the
clinician Delphi panel exercise were selected as having a
major interest in FM. The selected domains were distrib-
uted to all clinicians, who were asked to determine the
relative importance of each domain by distributing 100
points among the 40 domains. Clinicians were free to
assign points to as many or as few domains as they wished.
The number of points assigned to any particular domain
reflected its relative importance, with more points being
assigned to more important domains. In subsequent
rounds, clinicians were given their own response and the
group opinion for each domain (median, interquartile
range, and total range) from the previous round. They were
able to submit new scores or leave their scores unchanged.
In total, 3 rounds were conducted.
Patient Delphi methods. Overview. Patients were recruited
from the following sites: Seattle, Washington; Cincinnati,
Ohio; Ann Arbor, Michigan; and San Antonio, Texas. The
Delphi exercises were conducted between September 2005
and May 2006. The institutional review boards at each of
the 4 sites approved the protocol, and all patients provided
written informed consent after the study was explained
and their questions were answered and before study pro-
cedures were initiated. The patients were identified by the
investigators (LMA, LJC, PJM, and IJR) from outpatient
clinics or from registries of patients with FM at each of
these sites.
Entry criteria. Patients were eligible to participate in the
research if they were at least 18 years of age and met the
American College of Rheumatology 1990 criteria for FM
(1). Patients could not participate in the study if they had
a life-threatening health condition or an uncontrolled psy-
chiatric condition.
Patient Delphi exercise. A list of possible domains was
identified by patient focus groups (data available upon
request). Because this list was too extensive for inclusion
in the patient Delphi exercise, the patient Delphi exercise
started with a pretest round in which patients scored the
importance of each domain using a numeric rating scale
ranging from 0 (not at all important) to 10 (extremely
important). The aim of the pretest round was to narrow the
focus and reduce the number of domains generated during
the patient focus groups to be used in the subsequent
rounds of the Delphi exercise.
Based on the patients’ ratings of importance, 40 domains
from the pretest round were used in the Delphi exercise.
The language used over the course of the Delphi exercise
was carefully written and reviewed to ensure that the
instructions were clear to patients and that each domain
was understandable in terms of the FM experience or
referred symptom.
In rounds 1 and 2 of the patient Delphi exercise, partic-
ipants were asked to rank each domain as it applied to
them and impacted their life. Participants were instructed
to distribute 100 points among the 40 domains, giving
more points to the domains considered to be more appli-
cable and having more of an impact. In round 2, partici-
pants were presented with their score on each domain
from the previous round and the domain ranking results
from round 1 for all patients, which were revealed as the
mean and total range.
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The goal of the Delphi exercise was to come to a con-
sensus on prioritizing the domains that are important to
patients with FM. To achieve this goal, participants had an
opportunity to reflect on their response from round 1 in
the context of the responses from all other participants,
which were presented in an anonymous manner. Partici-
pants then repeated the exercise (round 2) with the oppor-
tunity to change their previous responses if desired.
For each of the 40 domains in the Delphi rounds, mean
and median values were calculated according to the points
allocated in each round and the overall exercise. The per-
centage of patients who endorsed the domain (i.e., allocat-
ing 1 point to the domain) was also calculated.
RESULTS
Clinician Delphi results. As reviewed by Mease et al
(16), 51 FM experts were approached to participate in the
clinician Delphi panel exercise and 23 completed all 3
rounds. Clinicians were asked to rate the importance of the
domains for assessment in a context called symptom mod-
ifying. The results of the Delphi exercise were presented to
the 2004 Outcome Measures in Rheumatology Clinical
Trials VII (OMERACT VII) FM workshop attendees.
OMERACT is an international consortium of clinical in-
vestigators and representatives of regulatory and scientific
agencies and biopharmaceutical companies who meet ev-
ery other year to determine relevant domains for assess-
ment in the rheumatic diseases and to develop and eval-
uate outcome measures for these domains. The findings of
the clinician Delphi were presented to workshop attendees
who then voted on the prioritization of domains in terms
of their potential inclusion in a core set of domains to be
assessed in FM research.
In general, there was a high level of agreement between
the Delphi clinicians’ median scores and the voting by the
OMERACT group (see Mease et al [16] for details). In
summary, pain was the key domain for clinicians, fol-
lowed by fatigue, patient global assessment, sleep quality,
health-related quality of life, physical function, treatment
side effects, depression, tender point, cognitive impair-
ment, anxiety, and clinician global assessment. The
OMERACT participants agreed that pain, fatigue, and pa-
tient global assessment ranked the highest among the do-
mains of assessment for clinical trials. The OMERACT
participants also recommended that health-related quality
of life be ranked as highly important, with an emphasis on
assessing multidimensional aspects of function rather than
simply physical function (16).
Patient Delphi results. In the patient Delphi panel, 100
patients with a physician-confirmed FM diagnosis partic-
ipated in the importance-rating task conducted in the pre-
test round. Of 100 patients (95% women) who completed
the pretest, 73 patients responded to round 1 of the Delphi
exercise and 84 patients responded to round 2.
Ages ranged from 23 to 74 years (mean age 49 years).
Other patient characteristics are reported in Table 1. The
majority of patients (52%) had been diagnosed with FM
between 1 and 4 years before this study took place. How-
ever, 67% of patients reported that they had experienced
FM symptoms for 5 years. Thirty-three percent were not
working due to FM. Forty-two percent of patients labeled
their health as poor or fair. Comorbidities were similar to
previous reports (18,19); depressive and chronic fatigue
syndrome symptomatology were identified in 57% and
55% of patients, respectively.
Patients were initially given a list of 104 domains (gen-
erated from patient focus groups, the results of which are
presented elsewhere [20]) organized according to 3 con-
cepts: FM symptoms (39 domains, e.g., abdominal pain,
dizziness, and weight gain), impact of FM on daily life (41
domains, e.g., difficulty cooking, lack of vitality, and loss
of job), and impact of FM on emotional well-being (24
domains, e.g., anger, feeling unmotivated, and irritability).
After the importance-rating task/pretest round, investiga-
Table 1. Patient characteristics*
Patient characteristic Sample (n  100)
Women 95 (95)









High school diploma or less 21 (21)







Full or part time 33 (33)
Part time due to FM 10 (10)
Not working due to FM or
applied for or receiving
disability
33 (33)
Looking for work 3 (3)






Divorced or widowed 18 (18)
Significant partner or married 63 (63)
Self-reported severity of FM
symptoms
Extremely severe/severe 43 (43)
Moderately severe 49 (49)
Mild/very mild 7 (7)
Comorbidities
Depression 57 (57)




Irritable bowel syndrome 51 (51)
Anxiety 49 (49)
* Values are the number (percentage) unless otherwise indicated.
FM  fibromyalgia.
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tors evaluated the importance of each domain to patients,
and important domains were condensed to finalize the 40
domains used in the Delphi exercise. The manner in
which the pretest domains were condensed to the final list
of 40 domains for the Delphi exercise is summarized in
Tables 2, 3, and 4. More than two-thirds (67.5%) of the
Delphi domains consisted of 2 items from the impor-
tance-rating task. For example, the Delphi domain prob-
lems with attention or concentration was based on 2 pre-
test items: difficulty concentrating and difficulty thinking
or “fibro-fog.” By combining conceptually related domains
identified as important at the pretest stage, it was possible
to ask patients about a broader range of symptoms with
fewer items. Of the 104 domains originally included at the
pretest stage, 92 were captured by the 40 Delphi domains,
but 12 were not included because they were not ranked as
important by most patients.
In the Delphi rounds, consistency was observed between
patients in terms of the hierarchy of domains with the
highest to lowest mean values. In round 1, all of the top 15
domains listed in Table 5 were allocated 1 point by at
least 68% of the patients (range 68–96%). In round 2, the
same domains were identified by at least 71% of partici-
pants (range 71–96%).
There were 7 domains with a median value of 0 (more
than half of all participants did not allocate any points) in
both rounds of the Delphi exercise: feeling alone, shame,
involuntary movements, changes in diet to help relieve
symptoms, cold hands, loss of job or career, and suscepti-
bility to colds or other infections. The results suggest that
these domains are seldom experienced by patients or may
not have a significant impact on patients’ lives relative to
the other domains listed.
Thirty-seven patients (53%) allocated more points to the
15 top-ranked domains in the second round than they had
in the first round (range 1–14 points). In other words,
Table 2. Delphi domains according to concept and their relevant score(s) from the importance-rating pretest round:
fibromyalgia symptoms*
Domains as presented in the Delphi exercise Domains from the pretest round (pretest mean score)
Pain or physical discomfort Pain (9.05)
Physical discomfort (8.30)
Lack of energy or fatigue Fatigue or tiredness (8.66)
Lack of energy (8.19)
Stiffness Stiffness (8.33)
Joints aching or pain Aching or painful joints (8.14)
Feeling tender where touched Feeling tender where touched (7.65)
Problems with attention or concentration (e.g., difficulty
concentrating on things, difficulty thinking, “fibro-fog”)
Difficulty concentrating (7.57)
Difficulty thinking or “fibro-fog” (7.04)
Difficulty moving, walking, or exercising Difficulty moving (7.21)
Inability to exercise (7.16)
Difficulty walking (5.98)
Memory problems Difficulty remembering things (7.15)
Memory loss (6.13)
Weight gain Weight gain (6.08)







Disorganized thinking (e.g., difficulty in expressing yourself,
difficulty in answering questions quickly, or difficulty
making plans)
Difficulty in answering a question quickly (5.90)
Difficulty in expressing yourself (4.79)
Numbness or tingling in your fingers or toes Numbness or tingling in your fingers or toes (5.35)
Headache or migraine Headache (5.61)
Migraines (4.37)
Being sensitive to outside factors (e.g., smells, sounds,
temperature changes, light, or touch)
Being sensitive to temperature or temperature changes (6.70)
Skin sensitivity (5.33)
Being sensitive to sounds (4.20)
Being sensitive to odors (4.14)
Being sensitive to light (3.88)
Cold hands Cold hands (4.62)
Susceptibility to colds or other infections Susceptibility to colds or other infections (4.45)
Involuntary movements Involuntary movements (3.85)
Dizziness Dizziness (3.63)
Stomach/intestinal symptoms (e.g., abdominal pain or
discomfort, nausea, or upset stomach)
Upset stomach (3.93)
Abdominal pain or discomfort (3.80)
Nausea (3.10)
* Score range 0–10.
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having received the feedback of the group’s results from
round 1, more than half of the patients changed their
distribution of points to be more in line with the feedback.
Twenty-two patients (31%) did the opposite and allocated
fewer points to the top-ranked domains in the second
round, changing their distribution of points to be less in
line with round 1 feedback (range 1–44 points). Eleven
patients (16%) did not differ in the number of points they
assigned to the top-ranked domains between round 1 and
round 2.
The scores of the 15 domains ranked highest overall and
in each round of the Delphi exercise are shown in Table 5
and are compared with the scores from the importance-
rating pretest round. In the importance-rating pretest
round, patients ranked domains from the FM symptoms
concept as the most important; this was reflected in the
Delphi exercise in which 11 of the top 15 Delphi domains
also came from FM symptoms. The remaining 4 domains
fell under the impact on daily life concept and corre-
sponded well to those ranked most important within this
group, with the exception of unpredictability of the symp-
toms, which was ranked as important in the importance-
rating task (mean 8.00) but as not important for assessment
during the Delphi exercise (mean 1.8).
Comparison of clinician and patient Delphi panel re-
sults. Overall, the domains ranked highest by patients
were similar to the domain rankings by the clinician Del-
phi panel. Pain was consistently ranked highest by both
panels. Fatigue, impact on sleep, health-related quality of
life, depression as a comorbid problem, and cognitive dif-
ficulty were also ranked highly, supporting the notion that
these domains are considered to be important for assess-
ment for both clinicians and patients. One domain ranked
highly by patients but not by clinicians/investigators was
stiffness.
Although patients did not directly refer to domains as
“patient global” or “health-related quality of life” as clini-
Table 3. Delphi domains according to concept and their relevant score(s) from the importance-rating pretest round: impact of
fibromyalgia on daily life*
Domains as presented in the Delphi exercise Domains from the pretest round (pretest mean score)
Unpredictability of the symptoms Unpredictability of the symptoms (8.00)
Having to push yourself to do things Having to push yourself to do things (7.93)
Impact on sleep (e.g., difficulty falling asleep, staying asleep,
or getting up in the morning)
Impact on sleep (8.46)
Difficulty staying asleep (7.53)
Difficulty in getting up in the morning (7.43)
Difficulty falling asleep (7.41)
Impacted/limited in doing normal daily life and household
activities
Impact on daily activities (7.63)
Limited in doing other day-to-day activities (7.37)
Impact on ability to make plans, accomplish goals, or
complete tasks
Interference with your ability to accomplish daily tasks
(7.34)
Hesitant to make plans (6.15)
Unable to make plans (5.71)
Social life impact (e.g., limited in doing your favorite hobby
or pastime or inability to travel)
Limited in doing your favorite hobby or pastime (7.08)
Social life impact (6.47)
Inability to travel (5.28)
Problems with medication (e.g., medication side effects or
reliance on medications)
Reliance on medication (6.79)
Treatment side effects (4.95)
Impact on family (i.e., relationship with your spouse or
partner and/or children)
Impact on your family (6.35)
Strain on your relationship with your spouse (3.95)
Impacted/limited in your ability to work, go to school or
college
Impact on work/school (6.85)
Interference with ability to accomplish tasks on the job
(5.47)
Interference in going to school or college (2.69)
Impact on intimacy and sexual relationships with spouse or
partner
Lack of libido or sex drive (5.01)
Sexual activity limitations (4.81)
Difficulty being sexually intimate with spouse or partner
(4.50)
Being unable to have sexual intercourse with spouse or
partner (4.50)
Changes in diet to help relieve symptoms Changes in diet to help relieve symptoms (4.60)
Loss of job or career Losing your job (4.32)
Loss of career (4.27)
Financial impact due to medical costs and health insurance Financial impact (5.63)
Medical costs (5.01)
Loss of health insurance (2.06)
Impact on driving (e.g., due to pain or fatigue or due to
memory problems)
Driving limitations (3.45)
Difficulty driving due to memory problems (3.19)
* Score range 0–10.
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cians did, the impact of FM on functioning was captured
by several of the domains identified by patients. These
domains included the impact on ability to make plans,
accomplish goals, and complete tasks, and impact on daily
life. Although side effects was included in the 40 domains
shown to patients during the Delphi exercises and was
ranked as important in the importance-rating task exercise,
it was not identified as an important domain for assess-
ment in the patient Delphi exercise, nor did patients refer
to or use a different domain name that may be related to
treatment or medication side effects (the overall mean for
the treatment side effects domain was 1.65).
DISCUSSION
The clinician and patient Delphi exercises described in
this report represent important and novel approaches to
Table 4. Delphi domains according to concept and their relevant score(s) from the importance-rating pretest round: impact of
fibromyalgia on emotional well-being*
Domains as presented in the Delphi exercise Domains from the pretest round (pretest mean score)
Feeling like you’ve lost who you are Feeling like you’ve lost who you are (5.90)
Anger or irritability Irritability (6.37)
Anger (4.85)
Frustrated (e.g., frustrated by limitations; frustrated by
encounters with family, friends, or physicians)
Frustrated about not being able to accomplish goals (7.38)
Frustrated about not being able to complete tasks (7.15)
Frustrated by encounters with your physicians (4.72)
Frustrated by encounters with family (4.39)
Frustrated by encounters with your peers (4.10)
Feeling like you are no longer valued by others (e.g.,
feeling as if people thought you were lazy, feeling
that you are a burden to your family, feeling like
the pace of your life is slower than most other
people, or feeling unreliable)
Feeling like pace of life is slower than most other people (6.31)
Feeling as if people thought you were “lazy” (5.87)
Feeling unreliable (4.94)
Feeling that you are a burden to your family (4.86)
Feeling like you are no longer valued by others (4.20)
Anxiety (e.g., nervousness or having panic attacks) Anxiety (5.23)
Nervousness (5.14)
Panic attacks (3.26)
Feeling alone (e.g., feeling like you are the only
person who has fibromyalgia or feeling isolated)
Feeling isolated (5.25)
Feeling alone (5.22)
Feeling like you are the only person who has fibromyalgia (2.86)
Shame (e.g., guilt or embarrassment) Guilt (4.17)
Embarrassment (3.71)
Ashamed (3.32)
* Score range 0–10.
Table 5. Comparison between the top 15 domains in each round of the patient Delphi exercise according to mean score,












Pain or physical discomfort 6.75 7.01 95 (95) 8.68
Joints aching or pain 5.78 5.58 90 (90) 8.14
Lack of energy or fatigue 5.53 5.48 96 (96) 8.43
Impact on sleep 5.22 5.45 92 (92) 7.71
Problems with attention or concentration 4.62 4.72 91 (91) 7.31
Stiffness 3.89 4.49 90 (90) 8.33
Disorganized thinking 3.62 3.61 85 (85) 5.35
Difficulty moving, walking, or exercising 3.54 3.52 86 (86) 6.78
Having to push yourself to do things 3.10 3.16 83 (83) 7.93
Depression 2.95 2.97 73 (73) 5.81
Feeling tender where touched 3.04 2.89 77 (77) 7.65
Impact on ability to make plans, accomplish goals, or complete tasks 2.79 3.12 78 (78) 6.40
Impacted/limited in doing normal daily life and household activities 2.95 2.65 82 (82) 7.50
Memory problems 2.51 2.68 80 (80) 6.64
Being sensitive to outside factors 2.75 2.46 70 (70) 4.85
* Percentage of patients who allocated at least 1 point to the domain during both Delphi exercises.
† Calculated from the mean scores of the individual pretest domains in Tables 2, 3, and 4.
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identification and prioritization of key domains of FM that
impact patients. The results of these exercises will be used
to construct a core set of domains for FM assessment in
research studies and clinical practice. Whereas clinician/
investigator Delphi exercises have been used in similar
processes in other disease states, we are not aware of this
technique being used in a large group of patients to pro-
vide a patient perspective on what domains are considered
important. The Delphi method is considered an ideal way
to gain understanding because it is conducted anony-
mously, minimizing the chance that a dominant person
will unduly influence all participants. By providing feed-
back on aggregate opinion, with allowance for subsequent
change of numeric prioritization, the exercise provides an
opportunity for consensus in areas where consensus is
lacking.
Despite uncertainties in the classification and etiology of
FM, there is increasing understanding and acceptance of
FM due to an increase in research of the pathophysiologic
processes that may be involved in the development of FM.
Furthermore, clinical trials have demonstrated meaningful
improvement in some symptoms of FM using a variety of
nonpharmacologic and pharmacologic therapies (5). By
ascertaining the key domains of FM when taking into
account the patient perspective, this study and the previ-
ous clinician Delphi study (16) provide guidance concern-
ing the key domains that should be assessed in the treat-
ment of patients with FM. The results demonstrate
consensus both within and between these constituencies
on the following domains: pain, fatigue, sleep disturbance,
multidimensional function, cognitive dysfunction, mood
disturbance, and the experience of stiffness. The results of
this study support the validity of focusing on these do-
mains in FM assessment and provide reassurance that the
domains are important to both clinicians and patients.
Despite the overall congruence of domain prioritization
Figure 1. Possible conceptual framework for fibromyalgia assessment. * Included based on
scores from importance-rating pretest round. PRO  patient-reported outcomes.
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between clinicians and patients, some discrepancies ex-
isted. Clinicians rated treatment adverse effects as impor-
tant to assess. Patients did not rate this domain as highly in
the Delphi exercise but ranked it as important in the im-
portance-ranking pretest. Research clinicians recognize
that for a treatment to be worthwhile, the balance of effi-
cacy and safety/tolerability must be acceptable, making
safety assessment absolutely necessary. Patients appreci-
ate the need for a treatment to be safe and tolerable, but
perhaps tend to focus on the impact of the disease on their
day-to-day experience. Any change in this experience as a
result of therapy effectiveness may be attributed to side
effects of FM rather than to treatment.
It is also possible that clinicians included side effects as
an important domain because they realized that this study
was part of a trial design strategy, whereas patients were
not aware of this fact and therefore placed this domain in
a lower priority. However, the exercise directions stated,
“Information gained from this study may help develop
new outcome assessments for fibromyalgia studies in the
future, which could potentially help in the development of
new treatments for fibromyalgia.” Given that patients were
required to read these instructions, patients should have
been aware that the results of this study would be used to
develop assessments for use in clinical trials. However, it
is possible that the patients did not completely understand
the instruction.
Additionally, patients considered stiffness to be a highly
important symptom domain. Clinicians might associate
the phenomenon of stiffness with conditions such as in-
flammatory arthritis and may not appreciate how stiffness
might occur in FM, thus failing to consistently address it
in discussions with patients.
Patients described problems with attention or concen-
tration, disorganized thinking, and memory problems as 3
different items within the top 15 domains. In the previous
study of the clinician Delphi (16), clinicians ranked dys-
cognition as the 10th priority, demonstrating their recog-
nition of its importance. However, dyscognition may not
be as well understood by clinicians, partly because of a
relative lack of research on this domain in FM, the absence
of effective measures or treatment for dyscognition in clin-
ical trials or practice, and possibly the difficulty patients
have in reporting it.
It was hypothesized that there may be greater variability
and range among patients when identifying 40 important
domains for FM, thus different approaches were used to
develop the domain list for the clinician Delphi and pa-
tient Delphi exercises. This difference needs to be consid-
ered because it may have impacted the results of the Del-
phi method. The list of 40 domains generated for the
patient Delphi was the result of the importance-rating task
in which 104 domains identified in patient focus group
research were reduced to 40 based on patients’ ranking of
importance and the combining of conceptually related
items. For the clinician Delphi panel, the list of 40 do-
mains was created through literature review and discus-
sion among the authors. It may have been informative to
have conducted a pretest item reduction process, similar
to that used among patients (i.e., the importance-rating
task), to allow clinicians the opportunity to select which
domains were most important from a larger pool. This may
have allowed some domains, such as dyscognition, global
status, and health-related quality of life, to have been
described more specifically than these broader terms.
However, the methods used followed standard and ac-
cepted Delphi techniques (7).
A comparison between the proposed conceptual frame-
work (Figure 1) and a review of the existing FM outcome
instruments indicates that there may be gaps between
what patients and clinicians say is important and what
currently available instruments are measuring. Given the
number of important FM concepts outlined in the concep-
tual framework, it is not necessarily the case that all con-
cepts will need to be assessed in clinical trials at any one
time. In fact, what is important is that the concept(s) (e.g.,
impact of FM on daily living or FM mobility) that is
targeted is measured and evaluated comprehensively by
an instrument(s) that includes all relevant items required
for a full assessment of that concept(s). If the full spectrum
of FM concepts were to be measured, it is likely that a
battery of instruments would be required for adequate and
comprehensive measurement (21).
FM impacts many aspects of physical and mental health,
function, and participation in life activities. In evaluating
the effectiveness of therapies, it is important to assess the
impact of these therapies on the full array of domains
considered important by both clinicians and patients as a
core set of domains.
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